GlassScriptPhysician profile
Keith R Hoerning
NPI 1164517413
$5,140.79
in general payments reported to CMS, 2019-2025
38 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $370 · 2021: $214 · 2022: $632 · 2023: $1,035 · 2024: $1,234 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,291.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $727.21 | 2023-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Novo Nordisk INC | $556.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $551.18 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $479.30 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Esperion Therapeutics, INC. | $283.12 | 2020-2022 | |
| Amgen INC. | $261.76 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $219.47 | 2019-2025 | |
| Corcept Therapeutics | $203.00 | 2024-2025 | Korlym |
| Abbott Laboratories | $169.03 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $151.18 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boston Scientific Corporation | $133.21 | 2023 | Watchman Access System |
| Regeneron Healthcare Solutions, INC. | $118.39 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $93.97 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Glaxosmithkline, LLC. | $93.82 | 2019-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $92.03 | 2019-2025 | Zepbound, Jardiance, Emgality |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Hoerning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.